JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications

Completed

Conditions: Stroke
Myocardial Infarction
Hemorrhage, Gastrointestinal
Kidney Diseases

First Posted Date: 2016-07-12

Last Posted Date: 2016-10-11

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 144337

Registration Number: NCT02830178

Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AL-335
Drug: Odalasvir (ODV)
Drug: Simeprevir (SMV)

First Posted Date: 2016-07-06

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 22

Registration Number: NCT02824315

Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Odalasvir (ODV)
Drug: AL-335
Drug: Placebo

First Posted Date: 2016-07-04

Last Posted Date: 2018-03-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT02821858

Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Domperidone
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2016-06-29

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 44

Registration Number: NCT02816853

Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Formulation A (ALS-008176)
Drug: Formulation G1 (ALS-008176)
Drug: Formulation B (ALS-008176)
Drug: Formulation G2 (ALS-008176)
Drug: Formulation C (ALS-008176)
Drug: Formulation G3 (ALS-008176)
Drug: Formulation D (ALS-008176)
Drug: Formulation H1 (ALS-008176)
Drug: Formulation E (ALS-008176)
Drug: Formulation H2 (ALS-008176)
Drug: Formulation F (ALS-008176)
Drug: Formulation H3 (ALS-008176)

First Posted Date: 2016-06-27

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 11

Registration Number: NCT02813460

Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2016-06-23

Last Posted Date: 2019-11-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 81

Registration Number: NCT02811978

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Phase 3

Completed

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: Esketamine Nasal Spray

First Posted Date: 2016-05-25

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1148

Registration Number: NCT02782104

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: AL-335
Drug: Odalasvir
Drug: Simeprevir

First Posted Date: 2016-05-06

Last Posted Date: 2019-11-20

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 365

Registration Number: NCT02765490

A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-61178104 Intravenous
Drug: JNJ-61178104 Subcutaneous
Drug: Placebo

First Posted Date: 2016-05-02

Last Posted Date: 2017-01-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 54

Registration Number: NCT02758392

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Phase 1

Withdrawn

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Mantle-Cell
Lymphoma, Follicular

Interventions: Drug: Duvortuxizumab
Drug: Ibrutinib

First Posted Date: 2016-04-19

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT02743546

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy